Danaher Q1 Results Down, Beats Market; Sees Higher Core Revenues In Q2, Backs FY25 View; Stock Up

Danaher

147.94 CHF -20.45%

• Charts
• News
• Analysen

Kaufen Verkaufen

(RTTNews) - Danaher Corp. (DHR), while reporting weak first-quarter results, but above market estimates, on Tuesday issued outlook for second-quarter revenue and fiscal 2025 earnings. Further, the company maintained annual core revenue growth view.

In pre-market activity on the NYSE, the life sciences and diagnostics company's shares were gaining around 2.8 percent to trade at $190.06.

For the second quarter 2025, the company anticipates that adjusted core revenue will grow low-single digits year-over-year.

For full year 2025, the company expects adjusted net earnings per share in the range of $7.60 to $7.75.

The Wall Street analysts on average expect the company to report earnings of $7.67 per share. Analysts' estimates typically exclude special items.

Further, the firm continues to expect adjusted core revenue for the year to grow approximately 3 percent year-over-year.

In its first quarter, net earnings fell to $954 million from last year's $1.09 billion. Earnings per share declined to $1.32 from $1.45 a year ago.

Adjusted net earnings per share were $1.88, compared to $1.92 last year. The analysts expected the company to report earnings of $1.64 per share.

Revenues decreased 1 percent to $5.74 billion from $5.80 billion in the prior year. Adjusted core revenue was flat year-over-year. Analysts expected revenues of $5.59 billion for the quarter.

Rainer Blair, President and Chief Executive Officer, stated, "Revenue, earnings, and cash flow exceeded our expectations in the first quarter-highlighted by continued momentum in bioprocessing and better-than-expected respiratory demand in our molecular diagnostics business."

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.